Abstract
Aims—To identify all young people prescribed growth hormone in the UK as of 1 October 1998 and to determine their age, sex, and the indication for therapy.
Methods—Cross sectional national postal audit through members of the British Society for Paediatric Endocrinology and Diabetes (BSPED) and other paediatricians identified as potential prescribers of growth hormone. Main outcome measures were age, sex, and numbers of children receiving growth hormone by diagnostic category, analysed throughout the UK and by NHS region.
Results—A total of 3228 children (aged 0.3 to 23.9 years) receiving growth hormone were identified by contacting 171 paediatricians (149 BSPED members). Of these, 2395 (74%) were identified who were under 16 years—representing 19.8/100 000 children in that age range in the UK—and in whom full data concerning diagnostic category were available. In the under 16s, there were 1209 (50.4%) boys and 1186 (49.6%) girls (excluding the 477 girls with Turner’s syndrome: 63% boys and 37% girls). A total of 78% of the prescriptions were for licensed indications (primary and secondary growth hormone deficiency, Turner’s syndrome, and chronic renal disease); 22% were for unlicensed indications (intrauterine growth restriction, bony dysplasia, Noonan syndrome, and other “short normals”). These proportions are similar to those reported in previous audits and by postmarketing surveillance from Pharmacia & Upjohn Ltd in the year 2000. Patterns of treatment were relatively uniform between regions.
Conclusions—A national audit of UK growth hormone prescription indicates uniform prescribing practice between regions, low levels of prescription beyond licensed indications, and stable patterns of prescribing practice over the past two years.
(Arch Dis Child 2001;84:387–389)

Keywords: growth hormone; audit; prescription

Growth hormone has been available for the treatment of short stature since the early 1960s. Early growth hormone preparations were derived from human pituitary extracts, but this source was withdrawn in 1985 following early reports of possible association with the subsequent development of Creutzfeldt–Jakob disease. However, within 12 months biosynthetic human growth hormone became available and unlike the product derived from the pituitary extract, natural sequence E coli derived human growth hormone was available in unlimited quantities. Currently, growth hormone therapy has been recommended for a number of licensed indications including growth hormone insufficiency, Turner’s syndrome, growth failure associated with chronic renal disease, and most recently, for the growth hormone deficiency associated with Prader–Willi syndrome.

Prior to 1985, a national committee, the Health Services Human Growth Hormone Committee, funded by the NHS, approved all growth hormone prescriptions in the UK. The committee reviewed the clinical history, indications for treatment, and arranged supplies of growth hormone derived from pituitary extracts. With the advent of human biosynthetic growth hormone, this committee was disbanded and the responsibility for prescription was devolved to the individual growth centres and local paediatricians. Under the internal market arrangements introduced into the NHS, the cost of the prescription was further devolved to the general practitioners, who collaborate in shared care arrangements with local paediatricians.

A consequence of these rearrangements in the method of growth hormone prescription was that there was no longer a central database, and regular audit of growth hormone prescription has proved difficult. The membership of the British Society for Paediatric Endocrinology and Diabetes (BSPED) includes all the paediatric endocrinologists in the UK; they carry the largest responsibility for growth hormone prescription. In 1998, the Society agreed that as a prelude to future longitudinal audit of growth hormone prescription, the Society would endeavour to determine how many children were on growth hormone as of 1 October 1998, and the indications for therapy.
Table 1 Numbers and indications for growth hormone (GH) therapy

<table>
<thead>
<tr>
<th>Code</th>
<th>Diagnosis</th>
<th>Total no. Rx</th>
<th>% males</th>
<th>Age range (median)</th>
<th>% of total GH Rx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Idiopathic growth hormone deficiency</td>
<td>656</td>
<td>68%</td>
<td>0.3–15.9 (11.5)</td>
<td>27%</td>
</tr>
<tr>
<td>2</td>
<td>Congenital growth hormone deficiency (e.g. septo-optic dysplasia)</td>
<td>225</td>
<td>61%</td>
<td>0.7–15.9 (8.4)</td>
<td>9%</td>
</tr>
<tr>
<td>3</td>
<td>Craniohypophyseal deficiency</td>
<td>91</td>
<td>58%</td>
<td>2.8–15.9 (12.2)</td>
<td>4%</td>
</tr>
<tr>
<td>4</td>
<td>Other acquired growth hormone deficiency (e.g. post-irradiation)</td>
<td>347</td>
<td>57%</td>
<td>0.5–15.9 (12.5)</td>
<td>14%</td>
</tr>
<tr>
<td>5</td>
<td>Renal disease</td>
<td>477</td>
<td>0%</td>
<td>2.4–15.9 (11.3)</td>
<td>20%</td>
</tr>
<tr>
<td>6</td>
<td>Turner syndrome</td>
<td>63</td>
<td>68%</td>
<td>3.0–15.9 (10.3)</td>
<td>3%</td>
</tr>
<tr>
<td>7</td>
<td>Intrauterine growth retardation</td>
<td>74</td>
<td>67%</td>
<td>2.3–15.6 (10.7)</td>
<td>3%</td>
</tr>
<tr>
<td>8</td>
<td>Noonan syndrome</td>
<td>44</td>
<td>68%</td>
<td>7.0–15.9 (12.2)</td>
<td>2%</td>
</tr>
<tr>
<td>9</td>
<td>Bony dysplasia</td>
<td>107</td>
<td>55%</td>
<td>2.7–15.8 (11.5)</td>
<td>4%</td>
</tr>
<tr>
<td>10</td>
<td>All others</td>
<td>311</td>
<td>61%</td>
<td>0.5–15.9 (11.9)</td>
<td>13%</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>2395</td>
<td></td>
<td></td>
<td>100%</td>
</tr>
</tbody>
</table>

Subjects and methods

In 1998, all clinical members of the BSPED (n = 149) in the UK were contacted and asked to provide details of patients on growth hormone therapy as of 1 October 1998; 39 BSPED members reported prescribing growth hormone. For simplicity, the diagnostic criteria were grouped into the categories shown in table 1. BSPED members were also asked to identify any other doctors not in the BSPED who might be prescribing growth hormone within their region. Twenty two further prescribers were identified; they were also contacted for similar details of growth hormone prescription.

Results

The BSPED membership reported a total of 2434 prescriptions, and the 18 non-members of the society reported an additional 794 prescriptions, giving a total of 3228. The age range of the children being treated at the time of audit was 0.3 to 23.9 years (median 12.2). There were 53% males (age range 0.5–23.9 years, median 12.6), and 47% females (age range 0.3–21.1 years, median 11.8).

Because of variable ascertainment of subjects aged 16 years or over, relating to referral to adult clinics, subsequent analysis was confined to those aged under 16 years. A total of 2395 subjects were thus identified, representing 19.8/100 000 children aged under 16 years in the UK, in whom full details of the diagnosis were available. There were 1209 (50.4%) boys and 1186 (49.6%) girls; excluding the 477 Turner girls changed the balance to 63% boys and 37% girls.

Table 1 summarises the indications for growth hormone therapy in these 2395 children. Overall, 78% of prescriptions were for licensed indications, including growth hormone deficiency (idiopathic, congenital, secondary (craniohypophyseal and other acquired), Turner’s syndrome, and renal disease); 22% of prescriptions were for other indications. The numbers and ages of children receiving growth hormone for the various indica-

Table 2 Comparison of numbers in treatment for different indications in the UK regions

<table>
<thead>
<tr>
<th>Region</th>
<th>Population aged &lt;16 y</th>
<th>GHD (code 1–4)</th>
<th>Turner (code 5)</th>
<th>Unlicensed (code 7–10)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. reported per 100 000</td>
<td>Age range (median)</td>
<td>No. reported per 100 000</td>
<td>Age range (median)</td>
</tr>
<tr>
<td>Anglia &amp; Oxford</td>
<td>119 870</td>
<td>107</td>
<td>9.6</td>
<td>0.5–15.6 (11.1)</td>
</tr>
<tr>
<td>North &amp; South Thames</td>
<td>2 812 660</td>
<td>242</td>
<td>8.6</td>
<td>4.0–15.9 (12.2)</td>
</tr>
<tr>
<td>North West</td>
<td>1 398 780</td>
<td>154</td>
<td>11.1</td>
<td>0.3–15.9 (10.4)</td>
</tr>
<tr>
<td>N &amp; Yorkshire</td>
<td>1 298 880</td>
<td>178</td>
<td>13.7</td>
<td>1.1–15.9 (10.6)</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>412 000</td>
<td>51</td>
<td>12.4</td>
<td>7.0–15.7 (11.7)</td>
</tr>
<tr>
<td>Scotland</td>
<td>1 019 480</td>
<td>118</td>
<td>11.6</td>
<td>5.0–15.9 (12.4)</td>
</tr>
<tr>
<td>South West</td>
<td>1 294 610</td>
<td>106</td>
<td>8.2</td>
<td>3.0–15.7 (11.2)</td>
</tr>
<tr>
<td>Trent</td>
<td>1 035 860</td>
<td>105</td>
<td>10.1</td>
<td>1.3–15.9 (11.0)</td>
</tr>
<tr>
<td>Wales</td>
<td>600 000</td>
<td>65</td>
<td>10.8</td>
<td>3.4–15.7 (11.7)</td>
</tr>
<tr>
<td>West Midlands</td>
<td>1 117 410</td>
<td>193</td>
<td>17.3</td>
<td>1.6–15.7 (11.8)</td>
</tr>
</tbody>
</table>

GHD, growth hormone deficiency.
cations were relatively uniform between the regions (table 2).

Discussion
With the abolition of the Health Services Human Growth Hormone Committee in 1985, it has been difficult to assess the numbers and therapeutic rationale for growth hormone prescription in the UK. Whereas licensed indications for growth hormone have been extended from “straightforward” growth hormone deficiency to children with Turner’s syndrome, chronic renal disease, and most recently Prader–Willi syndrome, the implication in relation to cost/benefit has been difficult to establish. The benefits of growth hormone treatment in some of these conditions have been debated and the use of growth hormone outside licensed indications has not been determined.

In 1998, the BSPED undertook this audit to establish prescribing practice in the UK. A total of 57 paediatricians prescribing growth hormone were identified, of which the majority, 39, were BSPED members. Many of these were directors of the original regional registers of growth hormone prescribers or their natural successors. Response rates to the audit were satisfactory (70% of consultants contacted provided full details of growth hormone prescriptions). Limitations of the audit might include a failure to identify all paediatricians and adult physicians prescribing growth hormone to children, particularly those prescribing within the private sector. It is also likely that some nephrologists initiating growth hormone therapy in patients with chronic renal disease were not identified.

Nevertheless, the number of children under 16 receiving growth hormone within the UK (2395) is a reasonable estimate, representing 19.8/100 000 children. The majority of children were being treated for licensed indications, whereas the remaining 22% were being treated for unlicensed indications. An audit of growth hormone therapy in Scotland completed in 1999 indicated that 20% of children were being treated outside of licensed indications. Postmarketing surveillance surveys carried out by Pharmacia & Upjohn Ltd reported 21% being treated outside licensed indications in 1994; more recently in 2000, in a survey of 2163 children, growth hormone deficiency, Turner’s syndrome, and other licensed indications accounted for 77% of prescriptions, the remaining 23% being for unlicensed indications.

The number of children receiving growth hormone for growth hormone deficiency (approximately 1/7334) is lower than that reported previously by the MRC working party in 1979 and the Utah growth study in 1994; even though the numbers of children developing growth hormone insufficiency following cranial radiotherapy or other oncological therapies have increased through the years. It is unlikely that “missed patients” could completely account for this discrepancy, as not all would be growth hormone deficient. Rather, it supports the clinical impression that the prevalence of growth hormone deficiency may be declining. The cause of this decline is not known but could partly relate to increasing rates of surgical delivery in infants with breech presentation.

Regional analysis of prescribing practice was reassuring, in that the percentages of growth hormone prescriptions for the different indications were similar. Some anomalies were invariable as referral practices are complex. For example, low rates of ascertainment in Wales reflected referral practice whereby short children from North Wales were referred to Liverpool, and the low number of children with craniofacial dysmorphia reflected uneven referral to regional centres, particularly in London.

Overall these data indicate relatively uniform prescribing practice throughout the UK, low levels of prescription beyond licensed indications, and stable patterns of prescribing practice over the past two years.

The membership of the British Society for Paediatric Endocrinology and Diabetes Clinical Trials/Audit Group comprises: T Cole, MDC Donaldson, DB Dunger (Chair), PC Hindmarsh, CJH Kelkar, and M Preece.

We would like to thank all members of the BSPED and other paediatricians from the RCPCH who provided us with details of growth hormone prescriptions. We would also like to thank Pharmacia & Upjohn for their assistance in collecting some of the data through the KIGS database.

UK Audit of Childhood Growth Hormone Prescription, 1998

J Hilken

Arch Dis Child 2001 84: 387-389
doi: 10.1136/adc.84.5.387

Updated information and services can be found at:
http://adc.bmj.com/content/84/5/387

These include:

References
This article cites 7 articles, 2 of which you can access for free at:
http://adc.bmj.com/content/84/5/387#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Child health (3922)
- Diabetes (339)
- Rheumatology (521)
- Sexual health (352)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/